1. Home
  2. NEOG vs ANAB Comparison

NEOG vs ANAB Comparison

Compare NEOG & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neogen Corporation

NEOG

Neogen Corporation

HOLD

Current Price

$6.05

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$44.62

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOG
ANAB
Founded
1981
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
1989
2017

Fundamental Metrics

Financial Performance
Metric
NEOG
ANAB
Price
$6.05
$44.62
Analyst Decision
Buy
Buy
Analyst Count
4
12
Target Price
$8.83
$63.80
AVG Volume (30 Days)
3.5M
751.8K
Earning Date
01-09-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$886,886,000.00
$169,467,000.00
Revenue This Year
N/A
$135.45
Revenue Next Year
$1.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
196.42
52 Week Low
$3.87
$12.21
52 Week High
$13.51
$45.32

Technical Indicators

Market Signals
Indicator
NEOG
ANAB
Relative Strength Index (RSI) 51.51 72.08
Support Level $5.82 $40.52
Resistance Level $6.08 $45.32
Average True Range (ATR) 0.32 2.65
MACD 0.00 0.35
Stochastic Oscillator 63.68 85.66

Price Performance

Historical Comparison
NEOG
ANAB

About NEOG Neogen Corporation

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: